论文部分内容阅读
目的探讨血清胸苷激酶1(TK1)在甲胎蛋白(AFP)阴性原发性肝癌诊断及介入疗效中的临床价值。方法采用增强发光免疫点印迹法检测45例AFP阴性[(7.15±4.03)ng/ml]原发性肝癌患者(A组)经导管肝动脉化疗栓塞治疗前、治疗后2个月及50例健康体检者(C组)血清TK1值。结果 A组TK1阳性率高于C组(46.7%vs.4.0%)(P<0.01)。A组术前TK1值高于C组[(2.34±2.45)pmol/L vs.(1.00±0.62)pmol/L](P<0.05);介入治疗后,A组的TK1值降为(0.96±1.37)pmol/L(P<0.05)。结论 TK1在其辅助诊断AFP阴性原发性肝癌及评估介入疗效中具有一定的临床价值。
Objective To investigate the clinical value of serum thymidine kinase 1 (TK1) in diagnosis and interventional treatment of alpha-fetoprotein (AFP)-negative primary liver cancer. Methods 45 patients with AFP-negative [(7.15±4.03) ng/ml] primary liver cancer (group A) were treated with enhanced luminescence immunoblot blot before and 2 months after treatment with transcatheter hepatic arterial chemoembolization and 50 cases were healthy. Physical examination (group C) serum TK1 values. Results The positive rate of TK1 in group A was higher than that in group C (46.7% vs. 4.0%) (P<0.01). The preoperative TK1 value in group A was higher than that in group C ((2.34±2.45) pmol/L vs. (1.00±0.62) pmol/L] (P<0.05); after interventional therapy, the TK1 value in group A was reduced to (0.96±) 1.37) pmol/L (P<0.05). Conclusions TK1 has certain clinical value in the diagnosis of AFP-negative primary liver cancer and evaluation of interventional efficacy.